Efficacy of Colchicine in the treatment of COVID-19

Evaluation of the effectiveness of Colchicine tablets in mortality and duration of ICU hospitalization in patients under mechanical ventilation diagnosed with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211017052786N1

Enrollment

Registered

2022-01-18

Start date

2022-01-21

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Colchicine (N-[(7S)-1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide) produced by (Seid SA) company is administered orally to patients

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: People who are definitely hospitalized for Covid-19 diagnosis and are under mechanical ventilation Minimum age age of 30

Exclusion criteria

Exclusion criteria: Patients over age of 60 The patients who are pregnant or have an infant child Patients with liver enzyme problems Patients who are intubated in less than 24 hours

Design outcomes

Primary

Measure	Time frame
CRP level of the patient's blood. Timepoint: The first and fifth day of study. Method of measurement: Patient blood test.;Patient's blood lymphocyte count. Timepoint: The first and fifth days of study. Method of measurement: Patient blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Hossein Moradi Rafigh

Ghoum University of Medical Sciences

Amirmmr287@gamil.com+98 25 3885 6440

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026